M aturity-onset diabetes of the young (MODY) is a form of NIDDM characterized by an early age of onset and autosomal-dominant inheritance (1). So far, three MODY-causing genes have been identified; namely, the hepatocyte nuclear factor4a (HNF-4a)/M0DYl on chromosome 20q, the glucokinase/M0DY2 on chromosome 7p, and the HNFla/M0DY3 on chromosome 12 q (2-4).
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The identification of the MODY genes has allowed diagnosis at the molecular level for a large portion of MODY patients. Mutations inM0DY3/HNF-la have been identified in several populations by means of direct sequencing (4-6). However, direct sequencing (expensive and time-consuming) or conventional single-strand conformation polymorphism (SSCP) are not routinely applicable. Radioactive SSCP involves radioactive labeling, and the silver-staining SSCP requires postlabeling.
SSCP protocols using multiple fluorescent labeling and an automated DNA sequencer (7) may be an interesting alternative. We have developed a new SSCP protocol, based on fluorescent end-labeling with an automated sequencer, using primers extended by universal M13 sequences (8) . This modification results in two advantages. First, the same couple of fluorescently labeled primers may be used to detect all exons and promoter regions of HNF-la, reducing the cost of the technique. Second, the polymerase chain reaction fragments extended at their 5' ends by the universal M13 primers can be readily sequenced using the M13 dye primers or the dideoxy terminator sequencing kits.
The protocol and the primers used for the HNF-la screening by SSCP are available in an on-line appendix at www.diabetes.org/diabetes/appendix.htm. To evaluate the accuracy of this method, we have tested 21 mutations previously identified by direct sequencing (4-6). We detected 20 out of the 21 mutations (95%) using a single set of experimental conditions. We did not detect the P379fsinsC mutation when using the above experimental condition or when modifying the concentration of the gel matrix components.
In addition, we screened for mutations in HNF-la exons and minimal promoter (14 Brazilian and 9 Spanish probands who had a clinical diagnosis of MODY and who tested negative for glucokinase mutations). We found six different mutations in the coding regions of HNF-la in seven subjects, and two Brazilian probands showed the mutations G31D and S594I. The mutations S121fsdelC, V133M, and V259D were found in Spanish probands. The P291fsinsC mutation in exon 4, found in two Spanish subjects, was previously described in three unrelated German families and in a British pedigree (5). Figure 1 shows SSCP patterns of wild alleles, alleles with common polymorphisms, and mutant alleles in exons 1 and 10.
We have also tested two obese black African subjects from Mali and the Carribean with the "atypical diabetes" commonly found in black African and African-American subjects. This form of diabetes is characterized by the acute onset of symptoms with severe hyperglycemia and/or ketoacidosis and initial insulin dependence (10) . Autoimmune markers of insulindependent diabetes and glucokinase mutations were absent. One black African patient from Mali carries a G574S mutation on exon 9. The role of HNF-la mutations in this form of diabetes requires further investigation.
Although direct sequencing remains the reference methodology for mutation identification, SSCP analysis may be rapid and cost-effective. The advantages of the fluorescent SSCP protocol in comparison with the silver staining are multiple. First, the same experimental conditions could be used (for all exons of HNF-la, 95% detection rate was obtained). Second, given the availability of different fluorescent labels, samples can be multiplexed (7) . Third, the use of size, standard in each lane, corrects lane-to-lane variations and allows a reliable detection of shifts in the SSCP patterns. Fourth, control alleles with common polymorphisms can be used to distinguish, without sequencing, the known silent variations from disease-associated mutations. Because HNF-la is very polymorphic, this feature could be cost-effective, since the results of the SSCP screening can be stocked as computer files that can be easily processed. Although the sensitivity of this SSCP protocol is high, it doesn't reach 100%, probably because of the limitation of the SSCP technique itself (10) . However, a better control of gel temperature on the automated sequencer by adapting an external cooling system might increase this sensitivity rate. For the time being, complementary techniques should be performed in suspicious cases of M0DY3 when no mutations are detected by SSCP. These include linkage analysis of polymorphic markers at the HNF-la locus in large MODY pedigrees, or direct sequencing in individual patients or small families not suitable for linkage analyses.
This method could be appropriate for routine genetic diagnosis of MODY3, especially in young nondiabetic offspring of affected individuals or in patients in early stages of diabetes, in order to provide appropriate medical counseling.
